-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: info
On April 15, the State Food and Drug Administration approved the application for the listing of the generic drug of Sugengglucose sodium, which means that this $1.
About 20 million patients in China receive general anesthesia every year
Muscle relaxants represented by rocuronium bromide are commonly used as anesthesia adjuvant drugs in surgical operations.
Sugammadex Sodium is the world's first selective muscle relaxation antagonist for reversing neuromuscular blocking agents.
Sugammadex Sodium Structural Formula
Sugammadex was developed by Merck and was launched in the EU in September 2008 (trade name: Bridion), in the United States in December 2015, and in China through the priority review process in April 2017 (trade name: Bridion) )
As a blockbuster product, it has naturally become the target of imitation by domestic enterprises.
It is said that the reason for the long-term unapproved generic drug of sugammadex sodium injection is that the result of the joint approval of the API and the preparation is "I", that is, the raw materials/excipients/packages that have not passed the joint review and approval with the preparation material
This time, after the approval of Yangzi Jiangshu Geng Sodium Glucose, the status of the API should also change to "A" accordingly
